StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ:EGRX opened at $1.30 on Thursday. The business has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.43. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.37.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at about $96,000. DGS Capital Management LLC grew its stake in shares of Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at about $453,000. Finally, RBF Capital LLC grew its stake in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares in the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.